NDA 209360 · La Jolla Pharma
Giapreza
Angiotensin Ii Acetate · Intravenous · Vasoconstrictor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 21, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
273
53 Phase 3, 35 recruiting
FAERS reports
300
273 serious, 95 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 22, 2026.
1. INDICATIONS AND USAGE GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)] . GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. ( 1 )
Mechanism: Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 21, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
- GIAPREZA · ANGIOTENSIN II ACETATE EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
- GIAPREZA · ANGIOTENSIN II ACETATE EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- GIAPREZA · ANGIOTENSIN II ACETATE EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Angiotensin Ii" as an intervention, any sponsor and status, largest first.
OMNI Medical Services, LLCResearch network
NCT03944447 · 200,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Cannabis, Medical · For: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury and 30 more
Sites: Boca Raton, Florida; Bradenton, Florida; Fort Lauderdale, Florida · 17 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT00153101 · 31,546 participants · Start Nov 2001 · Primary completion Jun 2008
Drug: Telmisartan; Combination of Telmisartan and Ramipril and 1 more · For: Cardiovascular Diseases
Sites: Athens, Alabama; Birmingham, Alabama; Phoenix, Arizona · 732 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00249795 · 9,016 participants · Start Jun 2003 · Primary completion Aug 2009
Drug: Irbesartan; placebo · For: Atrial Fibrillation; Cardiovascular Disease
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 30 sites in all
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailurePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00853658 · 7,064 participants · Start Mar 2009 · Primary completion Oct 2015
Drug: Enalapril; Aliskiren · For: Chronic Heart Failure
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 806 sites in all
- Multifactorial Intervention on Diabetes (MIDiab Study)Pivotal-lookingStatus unknown
Shandong Provincial HospitalGovernment (non-federal)
NCT03430284 · 6,300 participants (planned) · Start Apr 1, 2018 · Primary completion Dec 31, 2021
Drug: Pharmacotherapy · For: Diabetes Mellitus, Type 2
Sites: Jinan, China · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective72
- off label use31
- death26
- acute kidney injury25
- toxicity to various agents19
- distributive shock17
- peripheral ischaemia17
- hypotension16
- overdose16
- intestinal ischaemia15
- cardiac arrest13
- cardiogenic shock12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 7 |
| 2012 | 13 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 12 |
| 2019 | 29 |
| 2020 | 18 |
| 2021 | 30 |
| 2022 | 38 |
| 2023 | 43 |
| 2024 | 19 |
| 2025 | 34 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Xie X, Liu Y, Perkovic V, et al. · Am J Kidney Dis 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.
Kotani Y, Belletti A, D'Amico F, et al. · Crit Care 2024 · Meta-Analysis, Systematic Review
- ANGIOTENSIN II IN THE TREATMENT OF DISTRIBUTIVE SHOCK: A SYSTEMATIC-REVIEW AND META-ANALYSIS.
Xourgia E, Exadaktylos AK, Chalkias A, et al. · Shock 2024 · Systematic Review, Meta-Analysis
- ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
Leisman DE, Handisides DR, Busse LW, et al. · Crit Care 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
Carcel C, Haghdoost F, Shen J, et al. · Cephalalgia 2023 · Meta-Analysis, Systematic Review
- Effect of Angiotensin II Antagonism on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis.
Mahmoud A, Taha Y, Meece LE, et al. · ASAIO J 2022 · Meta-Analysis, Systematic Review
Sponsor: La Jolla Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.